A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome

Nasim Kiaie, Armita Mahdavi Gorabi, Peter E. Penson, Gerald Watts, Thomas P. Johnston, Maciej Banach, Amirhossein Sahebkar

Research output: Contribution to journalReview article

Abstract

The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD.

Original languageEnglish
Number of pages15
JournalDrug Discovery Today
DOIs
Publication statusAccepted/In press - 13 Sep 2019

Fingerprint

Liposomes
Atherosclerosis
Cardiovascular Diseases
Therapeutics
Angina Pectoris
Contrast Media
Vaccines
Stroke
Myocardial Infarction
Morbidity
Mortality
Pharmaceutical Preparations
Genes

Cite this

Kiaie, Nasim ; Gorabi, Armita Mahdavi ; Penson, Peter E. ; Watts, Gerald ; Johnston, Thomas P. ; Banach, Maciej ; Sahebkar, Amirhossein. / A new approach to the diagnosis and treatment of atherosclerosis : the era of the liposome. In: Drug Discovery Today. 2019.
@article{2a22dc49e3d243b28f92bfb36e364297,
title = "A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome",
abstract = "The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD.",
author = "Nasim Kiaie and Gorabi, {Armita Mahdavi} and Penson, {Peter E.} and Gerald Watts and Johnston, {Thomas P.} and Maciej Banach and Amirhossein Sahebkar",
year = "2019",
month = "9",
day = "13",
doi = "10.1016/j.drudis.2019.09.005",
language = "English",
journal = "Drug Discovery Today",
issn = "1359-6446",
publisher = "Elsevier",

}

A new approach to the diagnosis and treatment of atherosclerosis : the era of the liposome. / Kiaie, Nasim; Gorabi, Armita Mahdavi; Penson, Peter E.; Watts, Gerald; Johnston, Thomas P.; Banach, Maciej; Sahebkar, Amirhossein.

In: Drug Discovery Today, 13.09.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A new approach to the diagnosis and treatment of atherosclerosis

T2 - the era of the liposome

AU - Kiaie, Nasim

AU - Gorabi, Armita Mahdavi

AU - Penson, Peter E.

AU - Watts, Gerald

AU - Johnston, Thomas P.

AU - Banach, Maciej

AU - Sahebkar, Amirhossein

PY - 2019/9/13

Y1 - 2019/9/13

N2 - The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD.

AB - The consequences of atherosclerotic cardiovascular disease (ASCVD) include myocardial infarction, ischemic stroke, and angina pectoris, which are major causes of mortality and morbidity worldwide. Despite current therapeutic strategies to reduce risk, patients still experience the consequences of ASCVD. Consequently, a current goal is to enhance visualization of early atherosclerotic lesions to improve residual ASCVD risk. The uses of liposomes, in the context of ASCVD, can include as contrast agents for imaging techniques, as well as for the delivery of antiatherosclerotic drugs, genes, and cells to established sites of plaque. Additionally, liposomes have a role as vaccine adjuvants against mediators of atherosclerosis. Here. we review the scientific and clinical evidence relating to the use of liposomes in the diagnosis and management of ASCVD.

UR - http://www.scopus.com/inward/record.url?scp=85072400437&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2019.09.005

DO - 10.1016/j.drudis.2019.09.005

M3 - Review article

JO - Drug Discovery Today

JF - Drug Discovery Today

SN - 1359-6446

ER -